By: Stéphane Buhler, Helen Baldomero, Sylvie Ferrari-Lacraz, Anne-Claire Mamez, Stavroula Masouridi-Levrat, Dominik Heim, Jörg Halter, Gayathri Nair, Yves Chalandon, Urs Schanz, Tayfun Güngör, Grazia Nicoloso, Jakob R. Passweg, Jean Villard
Published: in Blood Advances 2021; 5 (17): 3377–3386.
Patients: 909
Highlights:
- aGVHD after unrelated HSCT most frequent in single HLA-DPB1 mismatches with high cell surface expression levels
- TCE nonpermissiveness and PIRCHE-II predictive of aGVHD